Lung Cancer Trial, Recruiting NCT05598528 Sponsor: Second Xiangya Hospital of Central South University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05598528
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are over 18 years old
  • You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a tissue or cell sample test
  • Your cancer is at an advanced or spread stage (stage IIIB-IV) that cannot be removed by surgery, or it has come back or spread after surgery
  • You have at least one tumor that can be measured and tracked using standard medical imaging
  • Your cancer has tested positive for a specific gene change called an EGFR mutation, confirmed by a tissue or fluid sample
  • You have been treated with a specific approved type of targeted drug (a third-generation EGFR-TKI) as your first treatment for this cancer
  • You are willing to share your medical records, scan results, and samples for research purposes, and agree that your data may be used for future research and product development
  • You are willing to take part in the study and sign a consent form

Who may not be able to join:

  • People who are unable to understand what the study involves or are unwilling to sign the consent form
  • Women who are currently pregnant or breastfeeding
  • People who have had another type of cancer within the last 3 years
  • People who are currently taking part in, or have taken part in, another clinical drug trial
  • People who have received any full-body (systemic) cancer treatment within the last 2 years

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
28 September 2021
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR); Progression-free survival (PFS); Differences in genomic profiles of tumor tissues and ctDNA clearance of third-generation EGFR-TKIs sensitive and primary drug-resistant NSCLC.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov